Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Eli Lilly and Company
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03343613CT.gov A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | — | Terminated | — | — | — |
NCT03099109CT.gov A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors | — | Completed | — | — | — |
NCT02937272CT.gov A Study of LY3200882 in Participants With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02791334CT.gov A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lodapolimab (this asset) | Eli Lilly and Company | P1 | CC · 42 |
| Panitumumab | Astellas Pharma Inc | P2 | BB |
| Irinotecan | Mirati Therapeutics Inc. | P4 | BB |
| Nivestim | Ankara Etlik City Hospital | P2 | BB |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Feladilimab | GlaxoSmithKline | P2 | BB |
| Carboplatin | Bristol-Myers Squibb | P3 | BB |
| Pralsetinib, Trans- | Seoul National University Bundang Hospital | P3 | BB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Lodapolimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P1 | CC · 47 |
| Cutaneous Melanoma | — | P1 | CC · 44 |
| Cancer | — | P1 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lodapolimab in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lodapolimab-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →